The event "Challenges of economic evaluation in the next decade" organized by BioInnova Consulting, in collaboration with Almirall, AstraZeneca, Chiesi, Lilly, Regeneron and Takeda, held yesterday at the Spanish National Academy of Medicine, was attended by AELMHU, represented by Beatriz Perales Zamorano, secretary and member of the Association.
The conference, inaugurated by Eduardo Díaz-Rubio, president of the Royal National Academy of Medicine of Spain (RANM), Borja Smith Aldecoa, general director for BioInnova Consulting, Meritxell Granell Villalón, market access and public affairs senior director at Almirall, Pilar Pasaron, government affairs head for AstraZeneca and José Vicente Galindo, pricing & market access associate director at Chiesi, allowed us to listen to experts in the field of healthcare and their opinions in round tables with different approaches:
▪ The first, entitled 'Perspectives from the scientific societies', moderated by Ana Rosa Rubio Salvador and with the participation of: José Francisco Soto Bonel, president of the Spanish Society of Health Managers(SEDISA), Victoria Mateos, president of the Spanish Society of Hematology and Hemotherapy (SEHH), Jose Manuel Carrascosa Carrillo, vice president of the organization area of public dermatology of the Spanish Academy of Dermatology and Venereology (AEDV) and Jaime Jesus Perez , president of the Spanish Vaccination Association (AEV).
▪ The second, under the title 'Perspectives from the public administrations', moderated by Marta Trapero Bertran and with the presentations of Jorge Aboal Viñas, general director of healthcare of the Galician Health Service (SERGAS), Manel Fontanet Sacristán, technician of the drug management of the Catalan Health Service (CatSalut), Gonzalo Gonzalez Morcillo, hospital pharmacist of corporate services of the Health Service of the Balearic Islands (IB-SALUT), María Luisa Nicieza, pharmacist attached to the general directorate of health planning of the Ministry of Health of the Principality of Asturias and Francisco Rodríguez, head of the service of therapeutic optimization, innovative drugs and advanced therapies of the general directorate of pharmacy of the Ministry of Health of the Valencian Community.
The last one, entitled 'Horizons in the economic evaluation of drugs and healthcare technologies', and moderated by José Manuel Martínez Sesmero, was attended by Nuria Amarilla, president of the Pharmaceutical Law Section of the Madrid Bar Association (ICAM), David Cantarero Prieto, representative of the Health Economics Association Andoni Lorenzo Garmendia, president of the Spanish Patients' Forum (FEP) Pedro Luis Sánchez Torres, director of the studies department of Farmaindustria and, representing AELMHU, Beatriz Perales, secretary and member of the board of directors.
After all of them, some common points emerged for all the interveners: Some reflections:
- It is necessary to establish an open dialogue to listen to all stakeholders (scientific societies, regulators, patients, pharmaceutical companies, etc.) for a quality, shared and accepted economic evaluation.
-Ensuring equity and quality is essential in the economic evaluation of drugs is an obligation to make the healthcare system sustainable,
- It is imperative to allocate more investment in healthcare and to improve the structure of the same to be able to cover all its future challenges, greater investment in healthcare and the need for demanding structural changes to ensure healthcare financing.
The event was closed by José Nieves González, general director of economic-financial management, Madrid Health Service (SERMAS), Teresa Millán, director of corporate affairs, Lilly Spain and Portugal, Roberto González Piqueras, country access head, Regeneron and Alonso Fernandez Nistal , Pricing and New Product Planning Head at Takeda.
